Compare Neurocrine Biosciences Inc (NBIX) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Vanguard Total International Stock Index Fund ETF trades at $87.92. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | VXUS | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Sector/Thematic |
52-Week High | $185.50 | $88.41 |
52-Week Low | $123.10 | $72.17 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
VXUS trades at $88.08, down 0.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF offers broad international stock exposure, excluding U.S. equities, with a low expense ratio of 0.06% as of Vanguard's latest disclosure in 2026. Recent news highlights institutional buying and long-term growth potential amid U.S. market concentration concerns.
Outlook is positive for diversification benefits and valuation discounts relative to U.S. stocks, supported by analyst optimism. Risks include foreign tax credit limitations in IRAs and emerging market volatility. Wall Street sentiment leans bullish due to improved global growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
